TAT(SZ:002433)2023-10-30 16:00Financial Performance - The company's total revenue for Q3 2023 was ¥116,880,641.48, a decrease of 38.00% compared to the same period last year[5]. - The net profit attributable to shareholders was -¥147,582,138.00, representing a significant increase of 361.16% in losses year-over-year[5]. - The basic earnings per share (EPS) was -¥0.19, a decline of 375.00% compared to the previous year[5]. - The company reported a decrease in operating profit of ¥123,015,583.82, a decline of 73.89% year-over-year, primarily due to heavy debt and insufficient working capital[12]. - The net profit for the reporting period decreased by 59.65%, amounting to a loss of ¥97,810,295.62, due to similar financial pressures[13]. - Total operating revenue for the current period is 378,017,542.78, a decrease of 45.1% compared to 698,250,038.08 in the previous period[30]. - Net profit for the current period is -261,783,861.95, compared to -163,973,566.33 in the previous period, indicating a worsening loss[31]. - Total comprehensive income for the current period is -263,434,137.60, compared to -157,384,430.86 in the previous period, indicating a larger loss[31]. Cash Flow and Liquidity - The company’s cash flow from operating activities showed a net outflow of ¥113,669,132.08, reflecting a decrease of 309.31% year-over-year[5]. - Cash received from sales of goods and services decreased by ¥265,275,449.68, a decline of 37.89%, primarily due to a significant reduction in e-commerce retail sales of pharmaceuticals[15]. - Operating cash inflow decreased by ¥448,667,269.22, a decline of 45.22%, mainly due to a substantial decrease in sales revenue[15]. - The net cash flow from operating activities decreased by ¥167,976,848.36, a decline of 309.31%, primarily due to an increase in repayment of loans[15]. - Cash and cash equivalents at the end of Q3 2023 were ¥24,131,036.01, down from ¥31,869,246.92 at the end of Q3 2022[33]. - The net increase in cash and cash equivalents for Q3 2023 was -¥5,727,089.85, compared to -¥40,823,001.44 in Q3 2022, indicating an improvement in cash management[33]. - The company reported a cash balance of ¥29,858,125.86 at the beginning of Q3 2023, down from ¥72,692,248.36 at the beginning of Q3 2022[33]. Assets and Liabilities - Total assets at the end of the reporting period were ¥6,046,959,924.34, down 7.86% from the end of the previous year[5]. - The company's current liabilities totaled CNY 1,715,909,719.06 as of September 30, 2023, down from CNY 1,898,538,827.62 at the start of the year[28]. - The company's total liabilities were CNY 2,583,361,714.35 as of September 30, 2023, compared to CNY 2,835,483,695.60 at the beginning of the year[28]. - The company's inventory as of September 30, 2023, was CNY 2,260,614,139.91, a decline from CNY 2,318,669,336.36 at the start of the year[27]. - The company's net loss increased to CNY -446,718,562.84 as of September 30, 2023, compared to CNY -193,038,960.40 at the beginning of the year[28]. Restructuring and Regulatory Issues - The company initiated a pre-restructuring process on September 26, 2023, as decided by the Shantou Intermediate People's Court, but this does not confirm entry into formal restructuring[24]. - The company has not yet received legal documents confirming entry into the formal restructuring process, leaving uncertainty regarding future proceedings[24]. - The company aims to optimize its asset-liability structure and enhance its operational and profitability capabilities through successful restructuring[23]. - The company received a notice from the China Securities Regulatory Commission regarding an investigation into information disclosure violations[21]. Research and Development - Research and development expenses decreased by 41.42% to ¥6,139,000.00, attributed to insufficient funds during the reporting period[11]. - Research and development expenses decreased to 6,123,337.75 from 10,452,744.66, reflecting a reduction of 41.5%[30]. Financing Activities - Cash inflow from investment activities increased by ¥218,338,109.30, a growth of 54891.70%, mainly due to significant cash recovery from the disposal of fixed assets[16]. - The net cash flow from investment activities increased by ¥218,281,613.89, a growth of 3062.75%, primarily due to cash recovery from the disposal of fixed assets[16]. - Cash received from financing activities decreased by ¥315,100,109.50, a decline of 59.85%, mainly due to a reduction in borrowings[18]. - The total cash inflow from financing activities was ¥211,399,890.50 in Q3 2023, compared to ¥526,500,000.00 in Q3 2022, showing a significant decrease[33]. - The total cash outflow from financing activities was ¥314,760,023.51 in Q3 2023, compared to ¥614,550,657.92 in Q3 2022, reflecting a reduction in cash outflows[33]. - The net cash flow from financing activities was -¥103,360,133.01 for Q3 2023, compared to -¥88,050,657.92 in Q3 2022, indicating a decline in financing activities[33].